The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans
Bonnie Ky, MD*,
Anne Burke, MD*,
Sotirios Tsimikas, MD ,
Megan L. Wolfe, BS*,
Mahlet G. Tadesse, ScD*,
Philippe O. Szapary, MD*,
Joseph L. Witztum, MD,
Garret A. FitzGerald, MD* and
Daniel J. Rader, MD*,*
* Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania
University of California San Diego, La Jolla, California.
View larger version (24K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Changes in OxLDL, Lp-PLA2, and ApoB-100 After Statin Therapy
(A) Changes in oxidized low-density lipoprotein cholesterol (OxLDL) after statin therapy as measured by the Mercodia assay. Mean Mercodia OxLDL (antibody 4E6) levels (mg/dl) at baseline and 16 weeks in placebo-, pravastatin 40 mg/day (prava40)-, atorvastatin 10 mg/day (atorva10)-, and atorvastatin 80 mg/day (atorva80)-treated groups. (B) Changes in lipoprotein-associated phospholipase A2 (Lp-PLA2) mass after statin therapy. Mean Lp-PLA2 mass (ng/ml) at baseline and 16 weeks in placebo-, prava40-, atorva10-, and atorva80-treated groups. (C) Changes in apolipoprotein B-100 particle (apoB-100) after statin therapy. Mean apoB-100 levels (mg/dl) at baseline and 16 weeks in placebo-, prava40-, atorva10-, and atorva80-treated groups.
|
|
View larger version (29K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Changes in OxPL/apoB and Lp(a) After Statin Therapy
(A) Changes in oxidized phospholipids/apolipoprotein B-100 particle (OxPL/apoB) after statin therapy. Mean percent change in OxPL/apoB levels (antibody E06) after 16 weeks in placebo-, prava40-, atorva10-, and atorva80-treated groups. (B) Changes in lipoprotein(a) [Lp(a)] after statin therapy. Mean percent change in Lp(a) after 16 weeks in placebo-, prava40-, atorva10-, and atorva80-treated groups. Abbreviations as in Figure 2.
|
|
View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 4 Changes in IC/apoB and MDA-LDL Autoantibodies After Statin Therapy
Mean percent change in immune complex (IC)/apoB formation and immunoglobulin (Ig)G and IgM malondialdehyde (MDA)-LDL autoantibodies after 16 weeks in placebo-, prava40-, atorva10-, and atorva80-treated groups. Abbreviations as in Figure 2.
|
|
View larger version (26K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 5 Changes in Total ApoB-IC Formation After Statin Therapy
Mean percent change in total ApoB IgG and IgM IC formation after 16 weeks in placebo-, prava40-, atorva10-, and atorva80-treated groups. Abbreviations as in Figures 2 and 4.
|
|
|
